AMGN Q3 2026 deep dive: robust product sales and pipeline advances drive guidance increase
AMGN Q3 2026 deep dive: robust product sales and pipeline advances drive guidance increase TradingView
Covered in this story
Analyst targets on Amgen
- Oppenheimer: $439 → $480 by Oct 2027 · Outperform via Investing.com India
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 11 Jun 2026.
Summary aggregated from TradingView's public RSS feed. The full reporting belongs to TradingView — please read it on their site.